Hidden in plain sight: urinary Cryptococcus neoformans missed by routine diagnostics in a patient with acute leukemia

Zoe F. Weiss1,2,3*, James E. DiCarlo1, David W. Basta1, Stephanie Kent1, Alexis Liakos2, Lindsey Baden2, Manfred Brigl1, Sanjat Kanjila2,4, Connie Cañete-Gibas5, Nathan P. Wiederhold5 and Sankha S. Basu1,3

Abstract
Cryptococcuria is a rare manifestation of localized cryptococcal disease. We present a case of Cryptococcus neoformans urinary tract infection in an immunocompromised host missed by routine laboratory workup. The patient had negative blood cultures, a negative serum cryptococcal antigen (CrAg), and "non-Candida yeast" growing in urine culture that was initially dismissed as non-pathogenic. The diagnosis was ultimately made by matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) from a repeat urine culture after transfer to a tertiary care center. Cryptococcus should be considered in the differential of refractory urinary tract infections growing non-Candida yeast.

Keywords: Cryptococcuria, Cryptococcus neoformans, Cryptococcal infection, MALDI-TOF MS, India-ink, Cryptococcal antigen

Background
Cryptococcus neoformans is a free living saprobic encapsulated yeast that is ubiquitous in the environment and typically causes infection in patients with immunocompromising conditions such as HIV, hematologic malignancy, or organ transplantation. The cryptococcal polysaccharide capsule is its main virulence factor, allowing it to evade host immunity and readily disseminate. Once inhaled, pulmonary infection can lead to hematogenous spread, most often to the central nervous system but occasionally to skin, bone, and rarely the prostate or bladder. Cryptococcuria is a rare clinical finding. One retrospective study in an 800-bed hospital over 12 years found an incidence of 0.56 patients per 100,000 [1]. Identification of C. neoformans growing from clinical samples traditionally involves routine microbiology workup including specific staining techniques along with selective and differential media. Though colony morphology is not a specific diagnostic feature, C. neoformans is typically opaque to white and mucoid appearing on blood agar, while strains lacking capsules may appear dry [2, 3]. Increasingly, the use of proteomic techniques such as MALDI-TOF MS and DNA sequencing of the internal transcribed spacer (ITS) region of the nuclear ribosomal DNA have replaced traditional phenotypic methods for identification from culture [4]. Additionally, the use of highly sensitive and specific serum and cerebrospinal fluid (CSF) lateral flow antigen assays to detect Cryptococcal capsular antigens from clinical samples have become important non-culture based diagnostic tools. There are no FDA approved CrAg assays for urinary samples. Cryptococcus may be missed from urine in laboratories that do not routinely identify all yeasts in urine cultures, as yeast is frequently a commensal or

*Correspondence: zoefreemanweiss@gmail.com

1 Department of Pathology, Brigham & Women's Hospital and Harvard Medical School, Boston, MA, USA
Full list of author information is available at the end of the article

© The Author(s) 2022. Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
non-pathogenic organism in urine samples, particularly in patients with indwelling Foley catheters. Here we describe a case of *C. neoformans* isolated only from urine identified initially by MALDI-TOF MS.

**Case**

A 77-year-old Caucasian man with a long-standing history of high-risk myelodysplastic syndrome with systemic mastocytosis and benign prostatic hyperplasia was admitted to an outside hospital in the Boston (USA) area with several weeks of fatigue, somnolence, weakness, weight loss, and worsening nocturia. Two weeks prior to his hospitalization, he reported receiving cephalexin at a local clinic for a urinary tract infection (no culture data available), however he continued to experience urinary frequency and pain. He had no recent or remote travel outside of the New England area.

On presentation he was hypothermic (31 °C), bradycardic (HR 40 bpm), and hypotensive (systolic blood pressure was 80 s-90 mmHg). His laboratory workup was notable for hypoglycemia (glucose 22 mg/dL), a creatinine of 1.5 mg/dL (baseline 1.4 mg/dL), and evidence of malignant transformation to acute myeloid leukemia (AML). His white blood cell (WBC) count was 57,000 cells/mcL with 23% blasts. Peripheral flow cytometry revealed new acute AML with myelomonocytic differentiation. His urinalysis revealed moderate leukocyte esterase, >50 WBCs per high powered field, and moderate nitrites and 135 WBCs per high powered field. The urine culture grew >100,000 colonies forming units (CFU) of yeast, which appeared as uniformly dry white colonies (Fig. 1A). Our laboratory protocol requires yeast species identification if the organism is predominant and >50,000 CFU. Using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS, VITEK MS, BioMerieux), the organism was identified as *Cryptococcus neoformans* with >99.9% confidence on two different instruments. An India ink stain of the urine culture isolate was requested for further confirmation of this unexpected finding and was negative (Fig. 1B). Serum CrAg (IMMY, Crypto-Latex Antigen Detection System; Immunomycoligics Inc., Norman, OK, USA) was negative on serial dilution. ITS, D1/D2 sequencing and susceptibility were performed at Fungus Testing Laboratory, University of Texas Health at San Antonio, San Antonio Texas and again confirmed as *Cryptococcus neoformans var. grubii* (VNI/ VNII) (see Additional file 1: Fig. S1) [5]. Susceptibility by broth microdilution revealed a fluconazole MIC of 4 mcg/ml.

Given negative blood cultures, negative serum antigen testing, and no neurologic symptoms (no headaches, meningeal signs, fevers), and thrombocytopenia, lumbar puncture and induction with amphotericin were deferred. The patient was started on oral fluconazole 800 mg once, then 400 mg daily for treatment of isolated cryptococcosis in the absence of evidence of disseminated disease. On day 30, four days into antifungal therapy, a repeat urine sample demonstrated yeast which grew with a more typical mucoid appearance for *Cryptococcus* (Fig. 1C), which was again confirmed as *C. neoformans* by MALDI-TOF MS and now stained positive by India ink (Fig. 1D). Serum CrAg remained negative. On day 35 the patient was discharged on fluconazole indefinitely. His urologic symptoms resolved with fluconazole therapy, although he sadly expired two months after discharge due to complications from AML, unrelated to cryptococcal infection.

**Discussion**

The cryptococcal capsule, largely composed of the polysaccharides glucuronoxylomannan and glucuronoxylomannogalactan, is an important virulence factor for infection and can morph in size depending on environmental pressures exerted by the host or artificial growth media. In vivo, the protective capsule allows for immune evasion through prevention of phagocytosis [2, 6] and numerous immunomodulating properties, including downregulation of pro-inflammatory cytokines and complement depletion. Phenotypic switching and differential capsular expression are associated with changes in virulence, with unencapsulated...
cells being relatively avirulent and rarely associated with clinical isolates [7]. In vitro, decreased expression of capsular phenotypes in the absence of environmental pressure may result in variable culture morphologies depending on growth conditions [3].

India ink is traditionally used to detect cryptococcal organisms in clinical specimens by revealing the polysaccharide capsule which appears as a "halo" around the organism due to the inability of the ink to penetrate the capsule (Fig. 1D). However, poor sensitivity in clinical samples [8] and morphological variability in culture media limits its utility [2, 3]. Use beyond CSF samples is not established. Case reports describe its use in urine samples [9].

The initial isolate from the urine culture for our patient appeared dry and non-mucoid, consistent with a lack of visible capsules on India ink preparation (Fig. 1A and B). Repeat urine culture while on antifungal therapy revealed an isolate that appeared mucoid and was India ink positive. Capsular expression is regulated by complex host environmental cues. The initial morphology may have been due to a reduced capsular expression in vitro versus selective isolation of a phenotypically capsule deficient strain at the time of collection. Antifungal therapy is also associated with modulation of capsule size while specific host immune responses can induce or select for a larger capsule [10, 11]. It is possible that the distinct change in
morphology was related to the host response to treatment initiation.

Identification of Cryptococcus in this case was achieved through urine culture plated to solid media followed by MALDI-TOF MS. Additional confirmation was sought using ITS and D1/D2 sequencing. In general, samples plated on 5% Sheep’s Blood agar or Sabouraud dextrose agar can readily grow Cryptococcus sp. at 37 °C as early as 1–2 days after culture inoculation, however some isolates may take up to 5 days [12]. Historically, selective and differential media, were used to identify Cryptococcus sp. Compared to Candida sp., which remain white, Cryptococcal colonies appear dark brown on agar containing Niger seed extract (Fig. 2). Further differentiation of C. neoformans and C. gattii can be accomplished using L-Canavanine glycine bromothymol blue containing media, with C. gattii metabolizing the glycine, increasing the pH and turning the colonies blue via the bromothymol blue indicator [13].

Less labor-intensive phenotypic methods have subsequently emerged. Biochemical assays, such as those employed by the API 20C AUX test strip by bioMerieux are an essential part of yeast identification in many microbiology labs. The use of MALDI-TOF MS for rapid proteomic identification of Cryptococcus from cultured isolates has increasingly replaced traditional phenotypic techniques with a high degree of accuracy, especially for the most common species of Cryptococcus (C. neoformans and C. gattii). Further improvements in commercial database curations are still required to discriminate among less common species [4]. Though sequencing remains the gold standard for species identification, costs and turnaround time limit its use in the routine clinical laboratory.

Given the limitations of microscopy, reduced availability and prolonged turnaround time for culture-based methods, clinicians world-wide still rely heavily on the use of rapid, point of care, lateral flow assays (LFA) to
quickly and accurately detect *Cryptococcus* antigen in serum and cerebrospinal (CSF). These dipstick tests use monoclonal antibodies embedded on an immunochromatographic test strip to signal the presence of cryptococcal capsular polysaccharide glucuronoxylomannan antigen. In a meta-analysis of 12 studies (primarily of HIV-positive individuals) Huang et al. reported the pooled sensitivity and specificity of CSF and serum CrAg to be ~98–99% respectively for cryptococcosis [14]. Serum cryptococcal antigen may be less sensitive, however, for localized forms of the disease [15] and other specimen sources (such as from urine) have not been well established or FDA approved. Huang et al. reported a sensitivity of 85% from urine CrAg with insufficient information for specificity calculation [14]. The poor performance of urine CrAg precludes its current use in routine laboratories [16].

A negative serum CrAg may be due to localized disease due to reduced sensitivity in this setting. A negative CrAg LFA may also occur in the setting of capsule deficient, or capsule reduced organisms, as this method is specific for the polysaccharide *Cryptococcus* capsule. Though this is a rare phenomenon it has been described in the literature [17]. False negative antigen testing can occur in two additional scenarios. In cases of overwhelming cryptococcosis and appropriate immune response, high levels of endogenous antibody may sequester free antigen and thus interfere with antigen testing, called the “Prozone Phenomenon”. Alternatively, the “Post-Zone Phenomenon” may also occur where excessive antigen relative to immunoassay antibodies prevent antibody-antigen cross linking required for immunochromatographic detection [18].

Our patient presenting with new AML had over a month of urological symptoms, an abnormal urinalysis, multiple negative routine blood and sputum cultures, negative serum CrAg, and urine cultures growing non-*Candida* yeast ultimately identified as *C. neoformans*. Cryptococcuria is a rare clinical entity that is typically associated with systemic cryptococcal disease and has been described in both immunocompromised and in immunocompetent hosts [19]. In one retrospective analysis of 58 cases of cryptococcuria, 46 (79.3%) had a CrAg positive in CSF and 39 (67.2%) in blood. In 8 cases, cryptococcuria preceded the diagnosis of disseminated cryptococcosis. As such, identification in the urine may be an early indication of disseminated disease [1, 20]. Cryptococcuria has also been described in cases of chronic prostatitis diagnosed by prostatic biopsy and may represent a potential reservoir for infection in males [21, 22]. Cases of pyelonephritis [23] and epididymitis [24] have also been reported.

We demonstrate a rare case of urinary *C. neoformans* initially missed due to a laboratory protocol that precluded the workup of non-*Candida* yeasts from urine and lack of clinical suspicion. The microscopically observed variability in colony morphology and India ink staining may be attributed to variable in vitro growth conditions, the presence of multiple strains, or possibly altered capsular expression in the setting addition of antifungal agents and subsequent immune response. India ink is not routinely used in clinical samples other than CSF and urine microscopy is not sensitive for this organism. Urine cryptococcal antigen testing is not recommended and serum antigen testing may be negative in localized disease or rarely in the setting of capsule deficient strains. False negatives may also occur due to both the “Prozone Phenomenon” and “Post-Zone Phenomenon” and clinicians should understand the limitations of antigen testing. Proteomic techniques, which are increasingly being incorporated into clinical laboratories, can reliably confirm the diagnosis from pure culture.

Cryptococcuria is a rare clinical entity and can be associated with systemic disease or a harbinger for systemic involvement as described in the literature. Clinicians should consider *Cryptococcus* in cases of treatment-refractory urinary tract infections with non-*Candida* yeast in immunocompromised hosts, even when serum antigen testing and blood cultures are negative. In these cases, clinicians should request further workup of non-*Candida* yeasts from urine if not routinely performed.

### Abbreviations
MALDI-TOF MS: Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry; AML: Acute myeloid leukemia; WBC: White blood cell; CrAg: Cryptococcal antigen; ITS: Internal transcribed spacer; CSF: Cerebrospinal fluid; LFA: Lateral flow assay.

### Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12941-022-00540-4.

### Additional file 1: Figure S1.
Maximum likelihood tree resulting from ITS sequence analysis of isolate UTHSCSA DI22-46 and sequences of representative strains of the *Cryptococcus neoformans* species complex obtained from GenBank. Confidence values at the nodes > 0.95 [25, 26] represent posterior probabilities from Bayesian analysis, > 80% represent bootstrap re-samplings. The scale bar shows expected number of changes per site. The maximum likelihood analysis was conducted in IQ-Tree using the substitution model TIM+F determined by corrected Akaike Information Criteria (AIC) and Model Finder both of which are implemented in IQ-Tree [27–29].

### Acknowledgements
Not applicable.

### Author contributions
ZFW, conceptualization, visualization, investigation, writing, reviewing and editing, JED; original draft preparation, reviewing and editing, visualization, investigation. DWB; original draft preparation, reviewing and editing,
visualization, investigation, SK; visualization, investigation, AK; Conceptualization, LB; project administration, MB; project administration, SK; project administration, CG; investigation, NW/investigation, SSB; project administration, supervision, conceptualization, manuscript preparation, reviewing and editing.

**Funding**
Not applicable.

**Availability of data and materials**
All data generated or analyzed during this study are included in this published article [and its supplementary information files].

**Declarations**

**Ethics approval and consent to participate**
Not applicable.

**Consent for publication**
Not applicable.

**Competing interests**
Authors declare they have no competing interests.

**Author details**
1. Department of Pathology, Brigham & Women’s Hospital and Harvard Medical School, Boston, MA, USA. 2. Division of Infectious Diseases, Brigham & Women’s Hospital and Harvard Medical School, Boston, MA, USA. 3. Department of Population Medicine, Harvard Pilgrim Healthcare Institute and Harvard Medical School, Boston, MA, USA. 4. Fungus Testing Laboratory, Department of Pathology and Laboratory Medicine, Long School of Medicine, University of Texas Health San Antonio, Texas, USA.

**Received:** 23 March 2022  **Accepted:** 20 October 2022  **Published online:** 12 November 2022

**References**

1. Kientzburanakul S, Sungkanuparp S, Buabut B, Pracharktam R. Cryptococcuria as a manifestation of disseminated cryptococcosis and isolated urinary tract infection. Jpn J Infect Dis. 2004;57(5):203–5.

2. Esher SK, Zaragoza O, Alspaugh JA. Cryptococcal pathogenic mechanisms: a dangerous trip from the environment to the brain. Mem Inst Oswaldo Cruz. 2018;113(7):e180057.

3. O’Meara TR, Alspaugh J. The Cryptococcus neoformans capsule: a sword and a shield. Clin Microbiol Rev. 2012;25(3):378–408.

4. Cohen J. Comparison of the sensitivity of three methods for the rapid identification of Cryptococcus neoformans. J Clin Pathol. 1984;37(3):332–4.

5. Randall RE Jr, Stacy WK, Toone EC, Prout GR Jr, Madge GE, Shadowy HJ, et al. Cryptococcal Cryptococcal yeasts: a plentiful and diverse species complex. J Infect Dis. 1988;157(5):1299–301.

6. van Duin JD, Cleare W, Zaragoza O, Casadevall A, Nosanchuk JD. Effects of verticillan in Cryptococcus neoformans. Antimicrob Agents Chemother. 2004;48(6):2014–20.

7. Nosanchuk JD, Cleare W, Franzt SP, Casadevall A. Amphotericin B and flucytosine affect cellular charge, macrophage phagocytosis, and cellular morphology of Cryptococcus neoformans at subinhibitory concentrations. Antimicrob Agents Chemother. 1999;43(2):233–9.

8. Gillespie SH. - Medical mycology. In: Gillespie SH, editor. Medical microbiology illustrated. Oxford: Butterworth-Heinemann; 1994. p. 113–24.

9. Klein KR, Hall L, Dmelt SM, Rysawy JM, Wohlfel SL, Wengenack NL. Identification of Cryptococcus gattii by use of l-canavanine glycine bromothymol blue medium and DNA sequencing. J Clin Microbiol. 2009;47(11):3669–72.

10. Huang HR, Fan LC, Rajibhasi B, Xu JF. Evaluation of a new cryptococcal antigen lateral flow immunassay in serum, cerebrospinal fluid and urine for the diagnosis of cryptococcosis: a meta-analysis and systematic review. PLoS ONE. 2015;10(5):e0127117.

11. Singh N, Alexander BD, Lortholary O, Diemer F, Gupta KL, John GT, et al. Pulmonary cryptococcosis in solid organ transplant recipients: clinical relevance of serum cryptococcal antigen. Clin Infect Dis. 2008;46(2):e12–8.

12. Brito-Santos F, Ferreira M de F, Trilles L, Muniz M de M, Veloso Dos Santos VG, Carvalho-Costa FA, et al. Preheating of urine improves the specificity of urinary cryptococcal antigen testing using the lateral flow assay. PLoS Negl Trop Dis. 2017;11(5):e005304.

13. Suguir A, Honna M, Yarnamoto T. Difficulty in diagnosing chronic meningitis caused by capsule-deficient Cryptococcus neoformans. J Neurol Neurosurg Psychiatry. 2005;76(10):1460–1.

14. Kojima N, Chimombo M, Kahn DG. False-negative cryptococcal antigen test due to the postzone phenomenon. AIDS. 2018;32(9):1201–2.

15. Bae MH, Namgoong S, An D, Kim WN, Kim SH, Park KH, et al. Two cases of cryptococcus developed as isolated cryptococciosis and disseminated cryptoccocosis. Korean J Clin Microbiol. 2011;14:148. https://doi.org/10.5145/kjcm.2011.14.4.148.

16. Pasqualotto AC, Bittencourt Severo C, de Mattos Oliveira F, Severo LC. Cryptococcosis. An analysis of 28 cases with emphasis on the clinical outcome and its etiologic agent. Rev Iberoam Microl. 2004;21(3):143–6.

17. Larsen RA, Bozzette S, McCutchan JA, Chiu J, Leal MA, Richman DD. Persistent Cryptococcus neoformans infection of the prostate after successful treatment of meningitis. California Collaborative Treatment Group. Ann Intern Med. 1989;111(2):125–8.

18. Xu L, Tao R, Zhao Q, Cheng J, Zhu B. An AIDS patient with urine retention. BMC Infect Dis. 2019;19(1):1051.

19. Hellman RN, Hinrichs J, Sigard G, Hoover R, Golden P, Hoffsten P. Cryptococcal yeasts and disseminated cryptococcosis in a renal transplant recipient. Arch Intern Med. 1981;141(11):128–30.

20. James CL, Lomax-Smith JD. Cryptococcal epididymo-orchitis complicating steroid therapy for relapsing polychondritis. Pathology. 1991;23(3):256–8.

21. Ronquist F, Teslenko M, van der Mark P, Ayres DL, Darling A, Höhna S, et al. MrBayes 3.2: efficient bayesian phylogenetic inference and model choice across a large model space. Syst Biol. 2012;61:539–42. https://doi.org/10.1093/sysbio/sys029.

22. Hoang DT, Chromomor O, van Haeseler A, Minh BQ, Vinh LS. UFBoot2: improving the ultrafast bootstrap approximation. Mol Biol Evol. 2018;35(2):518–22.

23. Nguyen LT, Schmidt HA, van Haeseler A, Minh BQ. IQ-TREE: a fast and effective stochastic algorithm for estimating maximum-likelihood phylogenies. Mol Biol Evol. 2015;32(1):268–74.

24. Akaike H. A new look at the statistical model identification. IEEE Trans Automatic Control. 1974;19:716–23. https://doi.org/10.1109/tac.1974.110705.

25. Kalyaanamoorthy S, Minh BQ, Wong TF, van Haeseler A, Jermiin LS. ModelFinder: fast model selection for accurate phylogenetic estimates. Nat Methods. 2017;14:587–9. https://doi.org/10.1038/nmeth.4285.

**Publisher’s Note**
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.